RecovryAI
Documentation ProvidedRegulatory Status Disclosed
Overview
RecovryAI offers Virtual Care Assistants (VCAs), which are physician-prescribed, patient-facing clinical AI designed to support individuals during post-operative recovery. These VCAs aim to extend clinical supervision from the hospital into the patient’s home, particularly during the period after discharge when patients may be less monitored.
- What it does: The VCAs provide procedure-specific recovery guidance, check in with patients, interpret their reported symptoms, and escalate deviations from expected recovery patterns to the care team. The system is built on structured medical reasoning rather than open-ended chat.
- Who it is for: RecovryAI’s VCAs are intended for patients recovering from surgery, with an initial focus on total joint arthroplasty. They are designed for use in care settings where patients are discharged home for recovery, addressing the period when over 80% of surgeries are outpatient procedures.
- How it fits a clinical or practice workflow: Physicians prescribe the VCA to patients. The AI then engages directly with patients, delivering validated guidance and alerting licensed providers when recovery deviates from expected patterns. This allows care teams to re-engage when their clinical judgment is required.
- Notable capabilities: RecovryAI’s Virtual Care Assistants have received Breakthrough Device Designation from the FDA. This designation is for medical devices that address serious conditions and show the potential for meaningful improvement over existing standards of care. The company is pursuing FDA authorization under a Class II pathway for patient-facing Software as a Medical Device (SaMD).
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Regulated, patient-facing clinical AI
- Clinician-prescribed, procedure-specific
- Delivers clinically validated recovery guidance
- Escalates deviations in recovery to licensed providers
- Designed, evaluated, and governed as regulated medical devices
- Provides clear, consistent guidance based on protocols
- Surfaces symptoms needing clinician attention with care team visibility
- Built on structured medical reasoning (not open-ended chat)
- Alerts care teams when recovery deviates from expected patterns
- Supports post-operative recovery, specifically Total Joint Arthroplasty (TJA)
Use Cases
- Post-operative recovery monitoring
- Patient engagement and guidance after discharge
- Early detection and escalation of recovery deviations
- Providing clinically validated recovery protocols
- Supporting patients during recovery from surgery (e.g., Total Joint Arthroplasty)
- Aligning with RTM reimbursement pathways for post-operative monitoring
What Physicians Need to Know
Evidence Base
RecovryAI's Virtual Care Assistants (VCAs) provide clear, consistent guidance based on procedure-specific recovery protocols and established clinical guidelines. Its medical reasoning is built on structured medical reasoning, not open-ended chat, and continuously evaluates patient-reported information against expected recovery trajectories.
Clinical Validation Studies
RecovryAI is nearing completion of a multi-site pivotal clinical study for post-operative recovery following total joint arthroplasty (TJA). This study evaluates VCA medical reasoning by measuring concordance between AI-generated recommendations and physician judgment across scores of thousands of real-world patient conversations, aiming for over 100,000 adjudicated AI-patient exchanges. A limited pilot phase indicated VCA system behavior generally aligned with physician judgment. The company has received FDA Breakthrough Device Designation and is pursuing FDA authorization under a Class II pathway for patient-facing Software as a Medical Device (SaMD).
Alert Fatigue Management
The platform is designed to manage routine, low-acuity patient concerns, escalating deviations from expected recovery patterns to the prescribing physician's care team with complete patient interaction history and relevant clinical context. This architecture allows clinicians to retain oversight and exercise final medical judgment, re-engaging only when their expertise is truly required, thereby reducing the burden of routine inquiries.
Override Rate Data
Specific override rate data is not explicitly provided. However, the system is designed to ensure clinicians retain oversight and exercise final medical judgment when deviations are escalated, implying a mechanism for physician review and potential override of AI recommendations.
Differential Diagnosis Support
RecovryAI's Virtual Care Assistants are focused on guiding patients through post-operative recovery and escalating deviations, rather than providing differential diagnosis support.
Guideline Update Frequency
The frequency of guideline updates is not explicitly stated. However, the system is built on established clinical protocols and structured medical reasoning, and its pursuit of FDA authorization implies a commitment to maintaining up-to-date and clinically relevant information.
Clinical Workflow Integration
RecovryAI's Virtual Care Assistants are physician-prescribed and patient-facing, designed to extend continuity of care from hospital discharge into home recovery. They integrate into the clinical workflow by providing continuous patient monitoring, delivering procedure-specific guidance, and alerting care teams with full context when recovery deviates from expected patterns. This frees clinical staff to focus on higher-acuity cases.
Decision Audit Trail
The platform is designed with auditability and accountability as key considerations, particularly in its pursuit of FDA authorization. It escalates deviations to the care team with the complete patient interaction history and relevant clinical context. The ongoing pivotal study involves adjudicating over 100,000 AI-patient conversations against clinical ground truth, indicating a robust record-keeping and audit process for evaluation and regulatory compliance.
Physician Tip
RecovryAI's Virtual Care Assistants are designed to be physician-prescribed, extending your oversight into the critical post-discharge recovery period. Leverage the system to offload routine patient inquiries and continuously monitor for deviations from expected recovery patterns. The comprehensive patient interaction history provided upon escalation allows for informed clinical judgment on higher-acuity cases. While the AI manages routine guidance, remember that final medical judgment remains with the clinician.
RecovryAI's patient-facing AI is designed to bridge the gap between hospital discharge and follow-up appointments, providing continuous monitoring and structured escalation. While specific EHR integration details are not fully elaborated, the system's ability to provide 'full context' to the care team upon escalation suggests a design compatible with existing clinical communication channels to ensure seamless information flow and timely intervention.
Details
| Category | Clinical Decision Support & Reference, Patient Engagement & Education, Telehealth & Virtual Care |
| Pricing | Unknown — unknown |
| Deployment | Patient-facing digital platform for post-operative recovery guidance and monitoring. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Pending AI-estimated RecovryAI has achieved Breakthrough Device Designation for its Virtual Care Assistants supporting post-operative recovery following total joint arthroplasty. A multi-site pivotal clinical study was completed in April 2026. A De Novo Class II Submission was made in May 2026, with FDA Authorization expected in Q4 2026. FDA engagement began in 2024 and has included multiple rigorous pre-submissions. |
| Integrations | |
| EHR | Not specified |
| Specialties | Orthopedics |
Social Proof
| Customers | unknown |
| Notable | unknown |
What the Web Says
RecovryAI develops Virtual Care Assistants (VCAs), which are physician-prescribed, patient-facing clinical AI designed to support post-operative recovery. The company has received FDA Breakthrough Device Designation and is pursuing De Novo authorization as a Class II medical device. Their pivotal study, involving 525 hip and knee replacement patients, recently completed its patient participation phase, with physician adjudication and statistical analysis underway.
Overall: PositiveStrengths
- Physician-prescribed and patient-facing AI for post-operative recovery.
- Received FDA Breakthrough Device Designation, allowing for earlier and more frequent engagement with the FDA.
- Undergoing rigorous clinical validation with a multi-site pivotal study involving independent physician assessment.
- Aims to extend continuity of care from hospital discharge into home recovery, addressing a critical gap in patient monitoring.
- Designed to provide clinically validated recovery guidance and escalate deviations to care teams with relevant clinical context.
- Potential to strengthen the surgeon-patient connection and improve patient outcomes by managing routine concerns and alerting clinicians to higher-acuity cases.
Limitations
- The VCA has not yet been authorized by the FDA and is not commercially available.
- No direct user reviews from G2, Capterra, or Reddit specifically for RecovryAI were found, only general discussions about AI in recovery or other AI tools with similar names.
- General concerns about AI in recovery from Reddit users include potential for blips and inaccuracies, not being a substitute for human interaction, and privacy issues with free AI platforms.
- One Reddit user expressed strong concerns about using AI for mental health recovery, calling it irresponsible and ignorant.
Based on reviews from: SimplyHired, Business Wire, RecovryAI Official Website, Orthopedic Design & Technology, Reddit, Trustpilot
Last updated: 2026-08-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate RecovryAI
Press & Coverage
Business Wire
RecovryAI Completes Patient Phase of Pivotal Trial Evaluating Its Clinical AI in Advance of FDA De Novo Filing
RecovryAI announced the completion of the patient phase of its pivotal trial, involving 525 patients and over 43,000 clinical conversations, in preparation for an FDA De Novo filing. The study evaluated their Virtual Care Assistants (VCAs) for postoperative recovery in total hip and knee arthroplasty patients.
2026-07
RecovryAI
The Regulatory Route to Prescribed AI: A Primer on Our FDA De Novo Pathway
This article from RecovryAI's CEO details the company's FDA De Novo pathway for its Virtual Care Assistants, explaining the regulatory process, milestones achieved, and the significance of FDA authorization for patient-facing clinical AI.
2026-07
OEM News
RecovryAI Wins FDA Breakthrough Nod for Patient-Facing Clinical AI
RecovryAI received FDA Breakthrough Device Designation for its Virtual Care Assistants, physician-prescribed, patient-facing clinical AI designed to support post-operative recovery, particularly for total joint arthroplasty. This designation allows for more frequent engagement with the FDA.
2026-03
STAT News
The FDA Just Gave a Generative AI Chatbot Breakthrough Status. Here's Why That Matters.
The FDA granted Breakthrough Device Designation to RecovryAI's generative AI chatbot, marking the first time such status has been given to a patient-facing generative AI product. This could set a precedent for a new FDA device classification for patient-facing AI.
2026-03
Medical Economics
RecovryAI wins FDA Breakthrough Designation for post-surgical AI platform
RecovryAI's Virtual Care Assistants, an AI software for monitoring post-surgical patients at home, received FDA Breakthrough Device Designation. This supports an AI-driven, physician-prescribed virtual assistant that follows clinical protocols and flags deviations to care teams.
2026-03
Business Wire
RecovryAI Announces FDA Breakthrough Device Designation for Patient-Facing Clinical AI
RecovryAI announced that the FDA granted Breakthrough Device Designation to its Virtual Care Assistants, physician-prescribed, patient-facing clinical AI designed to support patients during post-operative recovery. This milestone coincides with RecovryAI's emergence from stealth mode.
2026-03
AI Reporter America
RecovryAI Advanced FDA Regulatory Pathway with Completion of Pivotal Trial Patient Phase
RecovryAI completed the patient phase of its pivotal study for Virtual Care Assistants, involving 525 patients across three U.S. orthopedic centers. This marks a significant step towards their planned FDA De Novo submission for their patient-facing clinical AI.
2026-08
MDPI
A Review of Innovative Medical Rehabilitation Systems with Scalable AI-Assisted Platforms for Sensor-Based Recovery Monitoring
This review article explores innovative medical rehabilitation systems, focusing on AI, ML, and sensor technologies to create scalable platforms for personalized recovery and patient monitoring. It highlights the role of virtual assistants and chatbots in patient support.
2025-06
Videos
Product demos, reviews, and walkthroughs for RecovryAI.
FDA Redefining AI Breakthrough Standards: Voice-Based Heart Failure Detection, Post-Surgical Chat...
DX Today Podcast
Todayu2019s Top AI News & Breakthroughs ud83dudd25 u2014 Google's $0.25 AI & FDA's Cancer Breakthrough
ATA Next Edge
pigeon Recover treatment 127 ||#birds #shots #pigeon #kabutar #pigeontreatment
Ismail Pigeon Gallery
CAN I FIX THE RANGE ROVER SPORT SVR I WAS SCAMMED WITH?
Saving Salvage
Rescue Teams Recover Body of Missing Japanese Tourist in Skardu Mountains | Breaking News
Geo News
I Finally Found The Problem And It's BAD News For The Owner Of This R8!
REPerformance UK
Frequently Asked Questions
RecovryAI's Virtual Care Assistants are physician-prescribed, patient-facing AI designed to extend continuity of care from hospital discharge into home recovery. It provides procedure-specific guidance based on established clinical protocols and escalates deviations from expected recovery patterns to the care team with full clinical context, aiming to bridge the gap in post-discharge monitoring.
RecovryAI has received FDA Breakthrough Device Designation for its Virtual Care Assistants and is pursuing FDA authorization under a novel Class II pathway for patient-facing Software as a Medical Device (SaMD). The company emphasizes that trust is underwritten by FDA authorization, and its design ensures clinical responsibility and adherence to established protocols.
Unlike many existing clinical decision support tools that are clinician-facing, RecovryAI represents a new class of regulated, patient-facing clinical AI. It aims to provide continuous monitoring and guidance during the critical post-discharge period, where traditional episodic visits offer limited visibility into patient progress.
While specific pricing for RecovryAI is not detailed, the company states its design aligns with existing Remote Therapeutic Monitoring (RTM) reimbursement pathways and is well-positioned for upcoming CMS models. Healthcare AI pricing models often include per-provider, per-facility, per-episode, or outcome-based structures.
As with all AI, RecovryAI's effectiveness relies on the data it's trained on, meaning potential biases could arise from unrepresentative datasets, leading to disparities in performance across different patient groups. The system's medical reasoning is evaluated by measuring its concordance with physician judgment, and it is designed to escalate complex issues to human clinicians.
RecovryAI is currently conducting a multi-site pivotal clinical study to evaluate the safety and system behavior of its Virtual Care Assistants in total joint arthroplasty recovery. Data from a limited pilot phase indicated that the VCA system behavior generally aligned with physician judgment, supporting its advancement.
RecovryAI is designed to deliver procedure-specific recovery guidance based on established clinical protocols. For deviations from expected recovery patterns or complex scenarios, it escalates these situations to the prescribing physician's care team with complete patient interaction history and relevant clinical context, ensuring human oversight and final medical judgment.
Suggest an Edit →
| Last Verified: 2026-07-03 | First Added: 2026-05-31